Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated Dec. 1, 2021:
Effective Jan. 1, 2022:
- Coverage Exception HIM
- Health Care Provider Administered (HCPA) Biologic Immunomodulator
- HEMLIBRA
- Cholestasis Pruritus
- Kerendia
- Human Fibrinogen Concentrate
- Hemophilia Factor VIII
- Hemophilia Factor IX
- Coagulation Factor VIIa
- Coagulation Factor X
- Isturisa
- Natpara
- Continuous Glucose Monitoring Systems (CGM)
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.